Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Buspirone: multicenter efficacy study.

D Wheatley

    The Journal of Clinical Psychiatry
    |December 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Buspirone and diazepam effectively treated anxiety symptoms over three weeks, showing significant improvement. While both drugs were well-tolerated, diazepam caused more drowsiness than buspirone.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.

    ESMO open·2025
    Same author

    Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2025
    Same author

    Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2022
    Same author

    Counterpoint: Does Mastectomy Reduce Overall Survival in Early Stage Breast Cancer?

    Clinical oncology (Royal College of Radiologists (Great Britain))·2021
    Same author

    Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2020
    Same author

    Breast radiotherapy: less is more?

    Clinical oncology (Royal College of Radiologists (Great Britain))·2012
    Same journal

    Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

    The Journal of clinical psychiatry·2026
    Same journal

    Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

    The Journal of clinical psychiatry·2026
    Same journal

    Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

    The Journal of clinical psychiatry·2026
    Same journal

    Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

    The Journal of clinical psychiatry·2026
    Same journal

    Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

    The Journal of clinical psychiatry·2026
    Same journal

    The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

    The Journal of clinical psychiatry·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Clinical Psychology
    • Psychiatry

    Background:

    • Anxiety disorders are prevalent, necessitating effective treatment options.
    • Buspirone and diazepam are commonly prescribed anxiolytics with different mechanisms of action.
    • Comparative studies are crucial for understanding relative efficacy and safety profiles.

    Purpose of the Study:

    • To compare the efficacy and safety of buspirone, diazepam, and placebo in patients with anxiety.
    • To evaluate treatment outcomes over a 3-week period using the Hamilton Rating Scale for Anxiety (HAM-A).

    Main Methods:

    • A 3-week, double-blind, randomized controlled trial involving 131 patients with HAM-A scores >= 15.
    • Oral administration of buspirone, diazepam, or placebo, with a maximum dose of 10 mg three times daily.

    Related Experiment Videos

  • Voluntary reporting of side effects by participants.

    • Main Results:

    • All treatment groups showed significant improvement at 1 and 2 weeks.
    • Both buspirone and diazepam demonstrated further significant improvement at 3 weeks, unlike placebo.
    • The incidence of side effects was similar between buspirone and diazepam, though diazepam caused significantly more drowsiness.

    Conclusions:

    • Buspirone and diazepam are effective anxiolytic agents over a 3-week treatment period.
    • Buspirone offers a favorable safety profile with less drowsiness compared to diazepam.
    • These findings support the use of buspirone as an alternative to benzodiazepines for anxiety management.